Of course, safety and effectiveness must still be established, given concerns over the affect on the lungs. A late-stage trial is slated to wrap in time for the firm to submit the product in 2009. Naturally, Bryce Carmine, Lilly's global brand director told the UBS Global Life Sciences Conference, that he's "encouraged" by the safety of inhaled insuling, according to Medical Marketing & Media.
And why shouldn't he be encouraged? If nothing else, the Lilly device is unlikely to show up in head shops.